Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: A systematic review of the literature

Drug Safety

Volumn 34, Issue 12, 2011, Pages 1125-1149

  Younus, Muhammad ^a   Kissner, Michelle ^a   Reich, Lester ^a   Wallis, Nicola ^b  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Anastrozole; Aromatase inhibitors; Breast cancer; Early breast cancer; Exemestane; Letrozole; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; LIPOPROTEIN; PLACEBO; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE FREE SURVIVAL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY CANCER; ESTROGEN BLOOD LEVEL; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HEART DISEASES; HUMANS; HYPERCHOLESTEROLEMIA;

EID: 81055123622     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11594170-000000000-00000     Document Type: Review

References (71)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998 May 16; 351 (9114): 1451-67
2. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 May 14-20; 365 (9472): 1687-717
3. Fisher B, Redmond C, Brown A, et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986 Apr; 4 (4): 459-71 (Pubitemid 16117934)
4. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010 Aug 10; 28 (23): 3784-96
5. National Comprehensive Cancer Network. Breast Cancer Clinical Practice Guidelines in Oncology V.1.2010 [online]. Available from URL: http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf [Accessed 2010 Feb 2]
6. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007 Jul; 18 (7): 1133-44 (Pubitemid 47244357)
7. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004 Mar 11; 350 (11): 1081-92 (Pubitemid 38298988)
8. Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive earlystage breast cancer: a meta-analysis. Lancet Oncol 2006 Dec; 7 (12): 991-6 (Pubitemid 44804137)
9. Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 2007 Jul 1; 25 (19): 2664-70 (Pubitemid 47123171)
10. Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002 Jun 22; 359 (9324): 2131-9 (Pubitemid 34694019)
11. Coates A, Keshaviah A, Thü rlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrineresponsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007 Feb 10; 25 (5): 486-92 (Pubitemid 350002953)
12. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005 Jan 1-7; 365 (9453): 60-2
13. Thü rlimann B, Keshaviah A, Coates A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353 (26): 2747-57 (Pubitemid 43016814)
14. Boccardo F, Rubagotti A, Guglielmini P, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006 Jun; 17 Suppl. 7: vii10-4 (Pubitemid 43985170)
15. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007 Feb 17; 369 (9561): 559-70
16. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005 Aug 6-12; 366 (9484): 455-62 (Pubitemid 41111693)
17. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. JNatl Cancer Inst 2005 Sep 7; 97 (17): 1262-71 (Pubitemid 41535367)
18. Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008 Apr 20; 26 (12): 1948-55
19. Ingle JN, Tu D, Pater JL, et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 2008 May; 19 (5): 877-82 (Pubitemid 351627301)
20. Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 2008 Apr 20; 26 (12): 1965-71
21. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010 Feb 23; 121 (7): e46-215
22. Peters HW, Westendorp IC, Hak AE, et al. Menopausal status and risk factors for cardiovascular disease. J Intern Med 1999 Dec; 246 (6): 521-8 (Pubitemid 30003172)
23. Rosano GM, Chierchia SL, Leonardo F, et al. Cardioprotective effects of ovarian hormones. Eur Heart J 1996 Aug; 17 Suppl. D: 15-9 (Pubitemid 26278621)
24. Nabholtz JM, Mouret-Reynier MA, Durando X, et al. Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer. Expert Opin Pharmacother 2009 Jun; 10 (9): 1435-47
25. Lewis S. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women? Am Heart J 2007 Feb; 153 (2): 182-8 (Pubitemid 46096865)
26. Chlebowski RT, Anderson GL, Geller M, et al. Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use. Clin Breast Cancer 2006 Feb; 6 Suppl. 2: S58-64
27. Gandhi S, Verma S. Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter. Breast Cancer Res Treat 2007 Nov; 106 (1): 1-9 (Pubitemid 47498087)
28. Jones LW, Haykowsky M, Pituskin EN, et al. Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor: positive operable breast cancer. Oncologist 2007 Oct; 12 (10): 1156-64 (Pubitemid 350106346)
29. Lenihan DJ, Esteva FJ. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. Oncologist 2008 Dec; 13 (12): 1224-34
30. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003 Nov 1; 98 (9): 1802-10 (Pubitemid 37310221)
31. Buzdar A, HowellA, Cuzick J, et al.Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006 Aug; 7 (8): 633-43
32. Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008 Jan; 9 (1): 45-53
33. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010 Dec; 11 (12): 1135-41
34. Sawada S, Sato K, Kusuhara M, et al. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer. Acta Oncol 2005; 44 (2): 134-41 (Pubitemid 40523371)
35. Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrineresponsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 2008 Apr 20; 26 (12): 1972-9
36. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer (plus Supplementary appendix) [online]. Available from URL: http://www.nejm.org/doi/ suppl/10.1056/NEJMoa0810818/suppl-file/nejm-big-1-98-766sa1.pdf [Accessed 2010 Feb 2]).
37. N Engl J Med 2009 Aug 20; 361 (8): 766-76
38. Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 2007 Dec 20; 25 (36): 5715-22
39. Colleoni M, Giobbie-Hurder A, Regan MM, et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011 Mar 20; 29 (9): 1117-24
40. Markopoulos C, Polychronis A, Dafni U, et al. Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Ann Oncol 2009 Jan; 20 (1): 49-55
41. Markopoulos C, Polychronis A, Zobolas V, et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 2005 Sep; 93 (1): 61-6 (Pubitemid 41355992)
42. Hozumi Y, Suemasu K, Takei H, et al. The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results ofNational SurgicalAdjuvant Study BC 04, the TEAM Japan sub-study. Ann Oncol 2011 Aug; 22 (8): 1777-82
43. Lonning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005 Aug 1; 23 (22): 5126-37 (Pubitemid 46224021)
44. Geisler J, Lonning PE, Krag LE, et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 2006 Nov; 42 (17): 2968-75 (Pubitemid 44667475)
45. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005 Aug 1; 23 (22): 5138-47 (Pubitemid 46224022)
46. Dubsky PC, Jakesz R, Greil R, et al. Two years of tamoxifen followed by 3 years of anastrozole versus 5 years of tamoxifen alone in postmenopausal women with hormoneresponsive early breast cancer: efficacy results from 3, 714 patients from the Austrian Breast and Colorectal Cancer Study Group (ABCSG) trial 8 [abstract no. 534]. 46th Annual Meeting of the American Society of Clinical Oncology (ASCO); 2010 Jun 4-8; Chicago (IL)
47. Wojtacki J, KruszewskiW J, Lesniewski-Kmak K, et al. Shortterm effects of anastrozole therapy on serum lipid profile in patients with breast cancer, previously treated with tamoxifen. Preliminary report. Nowotwory 2001; 51 (1): 43-7 (Pubitemid 32435946)
48. van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011 Jan 22; 377 (9762): 321-31
49. Francini G, Petrioli R, Montagnani A, et al. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer 2006 Jul 17; 95 (2): 153-8 (Pubitemid 44050914)
50. Montagnani A, Gonnelli S, Cadirni A, et al. The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer. Eur J Intern Med 2008 Dec; 19 (8): 592-7
51. Aihara T, Takatsuka Y, Ohsumi S, et al. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 Study. Breast Cancer Res Treat 2010 Jun; 121 (2): 379-87
52. Markopoulos C, Dafni U, Misitzis J, et al. Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Res 2009; 11 (3): R35
53. Markopoulos C, Chrissochou M, Michailidou A, et al. Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anticancer Drugs 2005 Sep; 16 (8): 879-83 (Pubitemid 41215754)
54. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003 Nov 6; 349 (19): 1793-802 (Pubitemid 37362955)
55. Wasan KM, Goss PE, Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005 May; 16 (5): 707-15 (Pubitemid 40767090)
56. Sagara Y, Kosha S, Baba S, et al. Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients. Breast Cancer 2010 Jul; 17 (3): 212-7
57. Del Mastro L, Venturini M. ATAC trial update [letter]. Lancet 2005 Apr 2-8; 365 (9466): 1225
58. American Heart Association. Heart disease and stroke statistics-2010 update (at-a-glance version) [online]. Available from URL: http://lern.la.gov/ index.php/download-file/view/128/227/[Accessed 2010 Oct 19]
59. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007; 9 (3): R28
60. Ewer MS, Gluck S. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer 2009 May 1; 115 (9): 1813-26
61. Bundred NJ. The effects of aromatase inhibitors on lipids and thrombosis. Br J Cancer 2005 Aug; 93 Suppl. 1: S23-7 (Pubitemid 44324676)
62. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 Jul 13; 110 (2): 227-39 (Pubitemid 38924592)
63. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 2007 Sep; 18 Suppl. 8: viii26-35
64. Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 2005 Dec 11; 591 (1-2): 247-63 (Pubitemid 41654853)
65. Gudbrandsen OA, Rost TH, Berge RK. Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver. J Lipid Res 2006 Oct; 47 (10): 2223-32 (Pubitemid 44936133)
66. Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990 Aug 15; 82 (16): 1327-32 (Pubitemid 20238487)
67. Wasan KM, Ramaswamy M, Haley J, et al. Administration of long-term tamoxifen therapy modifies the plasma lipoprotein-lipid concentration and lipid transfer protein I activity in postmenopausal women with breast cancer. J Pharm Sci 1997 Jul; 86 (7): 876-9 (Pubitemid 27297503)
68. Markopoulos C, Chrissochou M, Antonopoulou Z, et al. Duration of tamoxifen effect on lipidemic profile of postmenopausal breast cancer patients following deprivation of treatment. Oncology 2006; 70 (4): 301-5 (Pubitemid 44670172)
69. Poss J, Custodis F, Werner C, et al. Cardiovascular disease and dyslipidemia: beyond LDL. Curr Pharm Des 2011; 17 (9): 861-70
70. Cuppone F, Bria E, Verma S, et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Metaanalysis of randomized trials. Cancer 2008 Jan 15; 112 (2): 260-7
71. McCloskey EV, Hannon RA, Lakner G, et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 2007 Nov; 43 (17): 2523-31 (Pubitemid 350086940)